NCT04735172Recruiting
Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Striatum and Subthalamic Nuclei in de Novo Parkinsonian Patients and Control Subjects
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Initially, the exploration of brain metabolism by Nuclear Magnetic Resonance Spectroscopy (MRS) of the high magnetic field proton (1H) (11.7T) applied to acute and chronic animal models of Parkinson's disease (PD) showed glutamatergic hyperactivity within the striatum, one of the components of the basal ganglia. Interestingly, acute administration of L-dopa and acute, subchronic and chronic deep brain stimulation of the subthalamic nucleus (STN) normalizes these neurochemical profiles. Investigators also show an increase in glutamate levels in the STN ipsilateral to the substantia nigra pars compacta (SNpc) damaged by the neurotoxin, expected phenomenon, but also and surprisingly in the STN controlateral to the lesion. A degeneration of dopaminergic neurons is also observed in the controlateral SNpc at the lesion suggesting that the hyperglutamatergy of the controlateral STN to the lesion could promote neuronal death in the SNpc and thus participate in the progression and lateralization of the PD. Using 3T MRS in PD patients, as in other studies in humans, investigators do not see changes in glutamate and glutamine levels in the putamen of Parkinsonian patients. This difference between animal and human studies can be explained: 1. by the different rate of progression between PD in humans and animal models with plasticity phenomena limiting glutamatergic hyperactivity, 2. by the effect of treatment in PD masking changes in glutamate metabolism, 3. by limiting sensitivity in the detection of metabolites (Glutamate, glutamine, GABA) at 3T. The 7T 1H MRS improves the dispersion of chemical shifts of the metabolites studied, increases the sensitivity of the measurement, makes it possible to select regions of interest of smaller volumes (1 cm3) and thus limits the magnetic susceptibility effects that degrade the quality of the measured signal. This makes it possible to reliably separate glutamate and glutamine peaks. In this context, investigators propose to study the metabolic changes in a homogeneous group of de novo Parkinsonian patients, naive to any treatment intended to replace the missing dopamine. The gain in spatial resolution, contrast and signal will allow better characterization of localized anomalies in small-volume structures such as basal ganglia, putamen and STN.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 28 Jan 2021
- Start date
- 7 Apr 2022
- Primary completion date
- 31 Aug 2029
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Parkinson disease
- NCT number
- NCT04735172
What you commit to
- Study type: Interventional
- Planned participants: 44
- From 7 Apr 2022 to the primary completion date, 31 Aug 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with "contra-indications" to an MRI exam (without administration of a gadolinium chelate): presence of metal parts in the body (electronic devices such as a pacemaker, a neurostimulator, a cochlear implant, prostheses, etc.), claustrophobia,
- taking any treatment that may interact with brain concentrations of neurotransmitters, such as all psychotropic drugs and in particular antidepressants, neuroleptics, benzodiazepines, antiepileptics,
- persons with "contra-indications" to an MRI examination (without administration of a gadolinium chelate): presence of metal parts in the body (electronic devices such as a pacemaker, a neurostimulator, a cochlear implant, prostheses, etc.), claustrophobia,
- taking any treatment that may interact with brain concentrations of neurotransmitters, such as: all psychotropic drugs and in particular antidepressants, neuroleptics, benzodiazepines, antiepileptics,
Other illness
- persons suffering from progressive neurological and psychiatric pathology,
Other
- Patients will be excluded:
- having a severe tremor (\> 3 for a trembling sub-item of UPDRS 3) making the MR examination impossible,
- pregnant women,
- treated by deep brain neurostimulation,
- patients under guardianship or guardianship or protection of justice,
- patients who are excluded from another study.
- Controls:
- pregnant women,
- persons under guardianship or trusteeship or protection of justice,
- people who are excluded from another study.
Who the study is looking for
- Patients will be included:
- suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb \& Lees, 1988; Hughes et al., 1992),
- the stage of the disease is I-II according to the Hoehn and Yahr scale,
- which do not receive dopaminergic treatment,
- duration of disease development 5 years,
- without major cognitive impairment (Moca \> 24)
- men or women aged 18 to 75,
- having understood and signed the informed consent form,
- members of a social security scheme.
- Controls:
- subjects male or female aged 18 -75 years
- subjects affiliated to a social security scheme.
- volunteers who have given their written consent.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Not yet recruiting |
| CHU Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.